Condition (MeSH)
Paraganglioma, Extra-Adrenal
ClinicalTrials.gov lists 10 trials for Paraganglioma, Extra-Adrenal or a narrower condition beneath it. National Cancer Institute (NCI) has the most among industry and government lead sponsors, with 2.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase
10 of the 10 trials are tagged with Paraganglioma, Extra-Adrenal itself; the rest are tagged with a narrower condition beneath it.
When did Paraganglioma, Extra-Adrenal trials start? (8)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Phase 1
- Phase 2
- Not applicable
- Observational
Top of scale: 2
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2023 | 2 |
| 2021 | 1 |
| 2019 | 1 |
| 2017 | 1 |
| 2015 | 1 |
| 2011 | 1 |
| 2010 | 2 |
| 2008 | 1 |
No forecast is made for this condition: it averages 0.4 trial starts a year over the five years to September, under the 5 a year the method needs.
Recruitment duration, a model prediction: none of the 10 trials evaluated at the 2026-10-09 snapshot is predicted and still running. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Paraganglioma, Extra-Adrenal trials in? (4)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1 | 2 |
| Phase 2 | 6 |
| Not applicable | 1 |
| Observational | 1 |
How many Paraganglioma, Extra-Adrenal trials are recruiting? (3)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Completed | 7 |
| Terminated | 1 |
| Unknown status | 2 |
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Paraganglioma, Extra-Adrenal trials? (1)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| National Cancer Institute (NCI) | 2 |
Which drugs are being tested for Paraganglioma, Extra-Adrenal? (3)
Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.
| Drug | Trials |
|---|---|
| Temsirolimus | 1 |
| EVEROLIMUS | 1 |
| Cabozantinib S-malate | 1 |
Interventions as named in the registry (9)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| SOC: Temozolomide | 2 |
| Lenvatinib 1 | 2 |
| Pazopanib Pill | 1 |
| X: Penpulimab | 1 |
| Contrast Enhanced Ultrasound (CEUS) | 1 |
Showing 5 of 9 interventions.
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which serious adverse events do Paraganglioma, Extra-Adrenal trials report? (10)
Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.
| Adverse event | Subjects affected | Trials |
|---|---|---|
| Hypertension | 2 | 1 |
| Anemia | 1 | 1 |
| Aspartate aminotransferase increased | 1 | 1 |
| Blood bilirubin increased | 1 | 1 |
| Bone pain | 1 | 1 |
Showing 5 of 10 adverse events.
Which publications cover Paraganglioma, Extra-Adrenal? (5)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Belzutifan for Advanced Pheochromocytoma or Paraganglioma. | The New England journal of medicine | 2025 | Yes |
| Carney Triad, Carney-Stratakis Syndrome, 3PAS and Other Tumors Due to SDH Deficiency. | Frontiers in endocrinology | 2021 | Yes |
| Phaeochromocytoma and functioning paraganglioma in childhood and adolescence: role of iodine 131 metaiodobenzylguanidine. | European journal of nuclear medicine | 1991 | Yes |
| Gastrointestinal stromal tumour. | Lancet (London, England) | 2013 | No |
| [Benign tracheo-bronchial tumors. Other tumors]. | Annales de chirurgie | 1979 | No |
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: prevalence, rare-disease identity, and sub-conditions in mesh.